

Date: 11.12.2025

To

BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Subject: Revocation of Suspension in Trading of Equity Shares of Vivimed Labs Limited

We are delighted to inform both exchanges, our valued shareholders, and market participants that BSE Limited and the National Stock Exchange of India Limited (NSE) have officially communicated their decision to revoke the suspension in trading of equity shares of Vivimed Labs Limited. As per the notifications received:

Date of Circular/Notice: December 10, 2025

Effective Date of Revocation: Trading in equity shares will resume from **December 18, 2025**.

This revocation marks a significant turning point, reinstating liquidity and enabling price discovery for our shareholders. The Company has diligently complied with all requisite regulatory norms, specifically addressing previous non-compliances under SEBI (LODR) Regulations, 2015. We assure you that we will continue in the same spirit for the years to come. We extend our sincere gratitude to both exchanges and our shareholders for their unwavering support and patience throughout this challenging period.


We look forward to commencing trading with renewed vigor and commitment to transparency, growth, and sustained shareholder value.

The official circulars detailing this revocation are available on the websites of BSE and NSE for further reference.(attached)


You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LIMITED



YUGANDHAR KOPPARTHI
COMPANY SECRETARY



Vivimed Labs Limited.

CIN : L02411KA1988PLC009465

Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka-585 403, India

T+91 (0) 8482-232045, F+91 (0) 8482-232436

Email: info@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

6-3-866/1/G1, 3rd Floor, GMR Towers,
Greelands, Begumpet, Hyderabad
Telangana-500 016, India.

GSTIN: 36AAACV6060A1ZQ

T 91(0) 40-6608-6608, F+91(0) 40-6608-6699

NSE/SOP/REV/1317

December 10, 2025

The Company Secretary
Vivimed Labs Limited
Plot No 78 - A Kolhar Industrial Area,
Bidar, Karnataka, 585403

Dear Sir/Madam,

Subject: Revocation of suspension in trading of Equity Shares

As per the captioned subject, it is hereby informed that the trading in Securities of your Company will be revoked w.e.f. December 18, 2025, in “Trade for Trade category (i.e., BE series)” as per the provisions of SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (“Master Circular”) (Erstwhile SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023).

In case of any further clarification required, you may contact below mentioned officers from Listing Compliance Operations Department:

- Ms. Sonam Yadav
- Ms. Harshita Chaubal

Yours faithfully
For **National Stock Exchange of India Limited**

Aseem Sehgal
Senior Manager

NOTICES

Notice No.	20251210-26	Notice Date	10 Dec 2025
Category	Company related	Segment	Equity
Subject	Revocation of Suspension in trading of equity shares of Vivimed Labs Ltd. (Scrip Code: 532660)		
Attachments	Annexure I.pdf		
Content			

Trading Members of the Exchange are hereby informed that the suspension in trading of equity shares of the below mentioned company will be revoked w.e.f. **December 18, 2025**. Pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, (Erstwhile SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/12 dated January 22, 2020 [and SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2018/77 dated May 3, 2018](#)), trading in the securities of the company will be resumed in "T" group.

Scrip Code	Name of the Company
532660	Vivimed Labs Ltd.

A profile of the Company is also attached as **Annexure I**.

The Information Memorandum of the aforesaid company will be available on the Exchange's website under Corporates → Corporate Filings → Information Memorandum → Revocation.

Further the trading members may please note that the above-mentioned scrip will be a part of Special Pre-open Session for IPO's & Relisted Scrips - Relist session on **December 18, 2025**.

For further information on SPOS, the trading members are requested to refer to the Exchange's notice no. 20120216-29 on **Enabling Special Pre-open Session for IPO's & Relisted Scrips**.

Trading Members are requested to take note of the same.

Yogendra Daxini

Deputy Vice President

Listing Compliance

December 10, 2025

Sonali Kurhade

Manager

Listing Compliance